Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_4
4
57%
Ph phase_3
2
29%

Phase Distribution

0

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution6 total trials
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
4(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Not yet recruiting1
Terminated1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (33.3%)
Phase 44 (66.7%)

Trials by Status

not_yet_recruiting114%
terminated114%
unknown114%
withdrawn114%
completed343%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_4

RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

NCT04485195
not_yet_recruitingphase_3

Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients

NCT04748991
completedphase_4

Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents

NCT03005366
completed

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

NCT01370629
terminatedphase_3

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

NCT00989001
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04485195Phase 4

RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

Completed
NCT04748991Phase 3

Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients

Not Yet Recruiting
NCT03005366Phase 4

Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents

Completed
NCT01370629

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Completed
NCT00989001Phase 3

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

Terminated
NCT01627106Phase 4

A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

Withdrawn
NCT01646281Phase 4

Vernakalant Versus Flecainide: Atrial Contractility

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7